PRME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Prime Medicine Inc (PRME) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has promising developments in gene editing and insider buying activity is strong, the financial performance shows significant losses, and technical indicators suggest no clear upward momentum. Additionally, the options data indicates bearish sentiment in the short term. For a long-term investor, it may be better to wait for more concrete progress toward value-creating milestones or improved financials.
The MACD is below zero and negatively contracting, indicating bearish momentum. The RSI is neutral at 32.297, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 3.267), with resistance at R1: 4.039. Overall, the technical indicators suggest no strong buy signal at this time.
Insider buying activity has increased significantly (18302.86% over the last month).
Analysts are optimistic about the company's 'one-and-done' gene editing therapies targeting significant unmet medical needs.
Revenue increased by 486.12% YoY in Q3 2025.
Net income dropped by -3.69% YoY, and EPS fell by -27.27% YoY in Q3
The stock is down -1.51% in pre-market trading, reflecting weak sentiment.
No recent news or congress trading data to support a strong buy case.
In Q3 2025, revenue increased significantly by 486.12% YoY to $1,225,000, but the company reported a net loss of -$50,582,000, down -3.69% YoY. EPS also declined by -27.27% YoY to -0.32. Gross margin remained at 100%. The financials highlight strong revenue growth but persistent losses.
LifeSci Capital initiated coverage with an Outperform rating and a $6 price target, citing promising gene editing therapies. JPMorgan maintained a Neutral rating, awaiting progress toward value-creating milestones. Analysts are cautiously optimistic but not overwhelmingly bullish.
